2.1
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older'.
Closed for comments This consultation ended on at Request commenting lead permission
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older'.
The dosage schedule is available in the summary of product characteristics for fenfluramine.
The list price for fenfluramine is £1,802.88 for the 120-ml (2.2 mg/ml) bottle and £5,408.65 for the 360-ml bottle (excluding VAT; BNF online accessed January 2024).
The company has a commercial arrangement. This makes fenfluramine available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation